Chemical Namelomitapide
Dosage FormCapsules (oral; 5mg, 10mg, 20mg)
Drug ClassInhibitors
CompanyAegerion Pharmaceuticals Inc.
Approval Year2012


  • Indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Juxtapid (lomitapide) Prescribing Information2012Aegerion Pharmaceuticals Inc., Cambridge, MA